Cancer Therapy

You have full text access to this OnlineOpen article

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis

  1. Kostantinos Zarogoulidis1,†,*,
  2. Eufimia Boutsikou1,
  3. Pavlos Zarogoulidis1,
  4. Ellada Eleftheriadou1,
  5. Theodore Kontakiotis1,
  6. Hellie Lithoxopoulou1,
  7. George Tzanakakis2,
  8. Ioannis Kanakis3,
  9. Nikos K. Karamanos3,‡,*

Article first published online: 6 APR 2009

DOI: 10.1002/ijc.24470

Issue

International Journal of Cancer

International Journal of Cancer

Volume 125, Issue 7, pages 1705–1709, 1 October 2009

Additional Information

How to Cite

Zarogoulidis, K., Boutsikou, E., Zarogoulidis, P., Eleftheriadou, E., Kontakiotis, T., Lithoxopoulou, H., Tzanakakis, G., Kanakis, I. and Karamanos, N. K. (2009), The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int. J. Cancer, 125: 1705–1709. doi: 10.1002/ijc.24470

Author Information

  1. 1

    Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece

  2. 2

    Department of Histology, School of Medicine, University of Crete, Herakleion, Greece

  3. 3

    Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece

  1. †

    Fax: +30-2310-992433.

  2. ‡

    Fax: +30-2610-997153.

*Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece

Publication History

  1. Issue published online: 24 JUL 2009
  2. Article first published online: 6 APR 2009
  3. Accepted manuscript online: 6 APR 2009 12:00AM EST
  4. Manuscript Accepted: 17 MAR 2009
  5. Manuscript Received: 23 FEB 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (213K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nigel Bundred, Antiresorptive therapies in oncology and their effects on cancer progression, Cancer Treatment Reviews, 2012, 38, 6, 776

    CrossRef

  2. 2
    Rebecca Aft, Jose-Ricardo Perez, Noopur Raje, Vera Hirsh, Fred Saad, Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates, Critical Reviews in Oncology/Hematology, 2012, 82, 2, 233

    CrossRef

  3. 3
    Michael Gnant, Philippe Clézardin, Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature, Cancer Treatment Reviews, 2012, 38, 5, 407

    CrossRef

  4. 4
    Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson, Edith A. Perez, Final 5-year results of Z-FAST trial, Cancer, 2012, 118, 5
    Direct Link:
  5. 5
    E.- F. Solomayer, G. Gebauer, P. Hirnle, W. Janni, H.- J. Luck, S. Becker, J. Huober, B. Kramer, B. Wackwitz, D. Wallwiener, T. Fehm, Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients, Annals of Oncology, 2012,

    CrossRef

  6. 6
    D. Santini, M. Tampellini, B. Vincenzi, T. Ibrahim, C. Ortega, V. Virzi, N. Silvestris, R. Berardi, C. Masini, N. Calipari, D. Ottaviani, V. Catalano, G. Badalamenti, R. Giannicola, F. Fabbri, O. Venditti, M. E. Fratto, C. Mazzara, T. P. Latiano, F. Bertolini, F. Petrelli, A. Ottone, C. Caroti, L. Salvatore, A. Falcone, P. Giordani, R. Addeo, M. Aglietta, S. Cascinu, S. Barni, E. Maiello, G. Tonini, Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study, Annals of Oncology, 2012,

    CrossRef

  7. 7
    Henry J. Henk, Satyin Kaura, Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan, Journal of Medical Economics, 2012, 15, 1, 175

    CrossRef

  8. 8
    Henry J. Henk, Satyin Kaura, April Teitelbaum, Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases, Journal of Medical Economics, 2012, 15, 1, 195

    CrossRef

  9. 9
    Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, Gero Luschin-Ebengreuth, Dietmar Heck, Christian Menzel, Raimund Jakesz, Michael Seifert, Michael Hubalek, Gunda Pristauz, Thomas Bauernhofer, Holger Eidtmann, Wolfgang Eiermann, Guenther Steger, Werner Kwasny, Peter Dubsky, Gerhard Hochreiner, Ernst-Pius Forsthuber, Christian Fesl, Richard Greil, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, The Lancet Oncology, 2011, 12, 7, 631

    CrossRef

  10. 10
    Luis Costa, Peter Harper, Robert E. Coleman, Allan Lipton, Anticancer evidence for zoledronic acid across the cancer continuum, Critical Reviews in Oncology/Hematology, 2011, 77, S31

    CrossRef

  11. 11
    Philippe Clézardin, Ismahène Benzaïd, Peter I. Croucher, Bisphosphonates in preclinical bone oncology, Bone, 2011, 49, 1, 66

    CrossRef

  12. 12
    Michael Gnant, Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data, Clinical Investigation, 2011, 1, 1, 97

    CrossRef

  13. 13
    Avani D. Joshi, John A. Carter, Marc F. Botteman, Satyin Kaura, Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom, Clinical Therapeutics, 2011, 33, 3, 291

    CrossRef

  14. 14
    Joaquim Bosch-Barrera, Sofía D. Merajver, Javier A. Menéndez, Catherine Poznak, Direct antitumour activity of zoledronic acid: preclinical and clinical data, Clinical and Translational Oncology, 2011, 13, 3, 148

    CrossRef

  15. 15
    Flaminia Coluzzi, Ilenia Mandatori, Consalvo Mattia, Emerging therapies in metastatic bone pain, Expert Opinion on Emerging Drugs, 2011, 16, 3, 441

    CrossRef

  16. 16
    Chantal Decroisette, Isabelle Monnet, Henri Berard, Gilles Quere, Herve Le Caer, Suzanna Bota, Clarisse Audigier-Valette, Laurence Geriniere, Jean-Marc Vernejoux, Christos Chouaid, Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer, Journal of Thoracic Oncology, 2011, 6, 3, 576

    CrossRef

  17. 17
    Allan Lipton, Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates, Expert Opinion on Pharmacotherapy, 2011, 12, 5, 749

    CrossRef

  18. 18
    Evangelos Terpos, Meletios A. Dimopoulos, Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications, Cancer Immunology, Immunotherapy, 2011, 60, 3, 305

    CrossRef

  19. 19
    Chiara Porta, Elena Riboldi, Maria Grazia Totaro, Laura Strauss, Antonio Sica, Alberto Mantovani, Macrophages in cancer and infectious diseases: the ‘good’ and the ‘bad’, Immunotherapy, 2011, 3, 10, 1185

    CrossRef

  20. 20
    Erika Hamilton, Timothy M. Clay, Kimberly L. Blackwell, New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response, Cancer Investigation, 2011, 29, 8, 533

    CrossRef

  21. 21
    H K Koul, S Koul, R B Meacham, New role for an established drug? Bisphosphonates as potential anticancer agents, Prostate Cancer and Prostatic Diseases, 2011, 15, 2, 111

    CrossRef

  22. 22
    Giannis Mountzios, Vassilis Ramfidis, Evangelos Terpos, Kostantinos N. Syrigos, Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data, Clinical Lung Cancer, 2011, 12, 6, 341

    CrossRef

  23. 23
    Birgit Cremer, Brenda M. Sandmaier, Wolfgang Bethge, Thoralf Lange, Valentin Goede, Udo Holtick, Michael Hallek, Kai Hübel, Reduced-Intensity Conditioning in Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Historical Perspective, Onkologie, 2011, 34, 12, 710

    CrossRef

  24. 24
    Reshma Mahtani, Raza Khan, Mohammad Jahanzeb, The Potential Application of Zoledronic Acid as Anticancer Therapy in Patients With Non–Small-Cell Lung Cancer, Clinical Lung Cancer, 2011, 12, 1, 26

    CrossRef

  25. 25
    Dulcinea Candelaria-Quintana, Zoneddy R. Dayao, Melanie E. Royce, The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer, Breast Cancer Research and Treatment, 2011, 132, 2, 355

    CrossRef

  26. 26
    R. Calderone, K. Nimako, A. Leary, S. Popat, M.E.R. O’Brien, Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication, European Journal of Cancer, 2011, 47, 11, 1603

    CrossRef

  27. 27
    Kyriaki Mystakidou, Irene Panagiotou, Elias Brountzos, Vassilios Kouloulias, Athanasios Gouliamos, Well-Differentiated Hand Liposarcoma with Bone Metastases Treated Successfully with Zoledronic Acid, Onkologie, 2011, 34, 12, 706

    CrossRef

  28. 28
    Hind T. Hatoum, Swu-Jane Lin, Amy Guo, Allan Lipton, Matthew R. Smith, Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis, Current Medical Research and Opinion, 2011, 27, 1, 55

    CrossRef

  29. 29
    Robert Coleman, Richard Cook, Vera Hirsh, Pierre Major, Allan Lipton, Zoledronic acid use in cancer patients, Cancer, 2011, 117, 1
    Direct Link:
  30. 30
    Mohamed S. Zaghloul, Rimoun Boutrus, Hisham El-Hossieny, Yasser Abdel Kader, Inas El-Attar, Mohamed Nazmy, A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer, International Journal of Clinical Oncology, 2010, 15, 4, 382

    CrossRef

  31. 31
    Jonathan Green, Allan Lipton, Anticancer Properties of Zoledronic Acid, Cancer Investigation, 2010, 28, 9, 944

    CrossRef

  32. 32
    Gareth Morgan, Allan Lipton, Antitumor Effects and Anticancer Applications of Bisphosphonates, Seminars in Oncology, 2010, 37, S30

    CrossRef

  33. 33
    Mohammad Jahanzeb, Vera Hirsh, Bisphosphonates in Lung Cancer: More Than a Palliative Therapy?, Seminars in Oncology, 2010, 37, S45

    CrossRef

  34. 34
    Allan Lipton, Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy, Seminars in Oncology, 2010, 37, S15

    CrossRef

  35. 35
    Helen L. Neville-Webbe, Michael Gnant, Robert E. Coleman, Potential Anticancer Properties of Bisphosphonates, Seminars in Oncology, 2010, 37, S53

    CrossRef

  36. 36
    Joanne E. Mortimer, Sumanta Kumar Pal, Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer, Seminars in Oncology, 2010, 37, S66

    CrossRef

  37. 37
    Alessandro Fatatis, Julia A. D'Ambrosio, Whitney L. Jamieson, Danielle L. Jernigan, Mike R. Russell, Microenvironment Factors Influencing Skeletal Metastases,
    Direct Link:
View Full Article (HTML) Get PDF (213K)